COMPASS Pathways Plc - American Depository Shares (CMPS) Covered Calls

Compass Pathways is a biotechnology company pioneering a new model of mental healthcare through its proprietary synthetic psilocybin, COMP360. Focused on difficult-to-treat conditions, the company combines pharmacological innovation with psychological support. Compass is currently leading the largest-ever clinical program for psilocybin therapy, aiming to deliver rapid and durable relief for patients suffering from treatment-resistant depression and PTSD.

You can sell covered calls on COMPASS Pathways Plc - American Depository Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CMPS (prices last updated Mon 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Compass Pathways plc (CMPS) is a clinical-stage biotechnology firm at the forefront of the psychedelic medicine revolution. Its flagship candidate, COMP360, is a proprietary synthetic formulation of psilocybin administered in a controlled setting alongside specialized psychological support. The company’s primary focus is Treatment-Resistant Depression (TRD), a market where patients have failed two or more conventional antidepressant therapies.

Unlike traditional daily medications, COMP360 is designed as an episodic intervention that can induce a rapid and durable clinical response. To support its commercialization, Compass has established strategic partnerships with major provider networks to integrate COMP360 into existing psychiatric infrastructure. This model utilizes established medical codes and facilities similar to those used for current neurostimulation and esketamine treatments.

Competitive Landscape

Compass operates in the emerging mental health biotechnology sector, where it competes for market share and clinical talent. Its most direct competitors in the psychedelic-inspired medicine space include Definium Therapeutics (formerly MindMed) and Cybin. In the broader TRD market, the company is often benchmarked against the success of Johnson & Johnson, whose Spravato has validated the commercial path for office-based interventional psychiatry.

The company also tracks against innovative biotech firms like Denali Therapeutics and Twist Bioscience, which operate within the broader pharmaceutical products industry. Compass’s primary competitive advantage is its "Breakthrough Therapy" designation from the FDA and its leading position in Phase 3 clinical trials. This clinical head start, combined with a robust patent portfolio, creates a significant barrier to entry for subsequent generic or alternative developers.

Strategic Outlook and Innovation

The strategic outlook for Compass in 2026 is centered on its New Drug Application (NDA) submission to the FDA. Following successful results from the COMP006 Phase 3 trial in February 2026, the company is pursuing a rolling submission process expected to conclude in late Q4. Management has accelerated commercial readiness plans by nearly a year, targeting a potential market launch by late 2026 or early 2027 should regulatory approval be granted.

Innovation is also expanding beyond depression into Post-Traumatic Stress Disorder (PTSD), where the FDA accepted an Investigational New Drug application in early 2026. This move unlocks a second major indication in a 13-million-patient U.S. market. With a strengthened balance sheet following a $350 million capital raise in early 2026, Compass is well-funded to transition from a research-focused biotech into a commercial-stage leader in the field of interventional psychiatry.

Want more examples? CMPR Covered Calls | CMRE Covered Calls